3 Japanese Dividend Stocks Offering 5% Plus Yield For Steadier Income

Energy markets continue to react to developments around the Strait of Hormuz, and that keeps inflation and central bank policy in focus. Many investors are looking for steadier income that does not depend on guessing every macro twist. Well covered dividend yields above 5% can help cushion portfolios when headlines are noisy. This article highlights three Dividend Powerhouse stocks from the screener that currently offer such income potential.

The three stocks covered below are just a sample from this idea. The full screen surfaced 445 more companies with similarly compelling dividend stories that are not included here. To identify and analyze income opportunities that fit your own risk and return goals, head straight into the Dividend Powerhouses (3%+ Yield) screener.

Canon (TSE:7751)

Overview: Canon is a global equipment manufacturer that earns most of its money from office and production printing systems, but also has sizable businesses in medical imaging, cameras and video equipment, and industrial machinery such as semiconductor and display manufacturing tools.

Operations: Canon generates around ¥2.5t in revenue from Printing, roughly ¥1.1t from Imaging, about ¥579b from Medical and around ¥347b from Industrial equipment, with smaller contributions from other corporate activities.

Market Cap: ¥3.8t

Income focused investors may find Canon worth a closer look. The stock trades on a P/E of 11.1x, while the internal value estimate and cash flow model both sit above the current price. Recent half year results showed higher sales and net income, helped by margin improvement as net profit margins moved from 3.6% to 7.4%. A sizeable buyback program in 2026 has also been shrinking the share count. The trade off is an earnings growth outlook that is steady rather than rapid, an unstable historical dividend record and some governance concerns around board independence and director turnover.

Canon’s higher margins and buybacks hint at a story that current P/E and headline dividend history might not fully capture. For a fuller picture, including key income risks and support factors, see the analysis report for Canon

Build your own Canon-style dividend shortlist

Canon and the two other Dividend Powerhouse stocks here all came from a single screen, but the real value lies in creating filters that match your own income and valuation rules. Use our flexible Screener to combine dividend, balance sheet and valuation checks, or start with any of our curated Investing Ideas.

Daiichi Sankyo Company (TSE:4568)

Overview: Daiichi Sankyo Company is a global pharmaceutical company focused on cancer, cardiovascular and metabolic, neurological and vaccine treatments, with key oncology drugs like Enhertu and Datroway used across multiple solid tumors and blood cancers, alongside therapies for conditions such as hypertension, high cholesterol, osteoporosis, diabetes and migraine.

Operations: Daiichi Sankyo Company generates about ¥2.2t in revenue from its Pharmaceutical Operation segment.

Market Cap: ¥4.8t

Daiichi Sankyo Company stands out in the Dividend Powerhouses screener because its income story is tied to a growing oncology franchise rather than a slow moving mature portfolio. New approvals for Datroway and Enhertu across breast and lung cancers are widening the treatment pool, while a broad antibody drug conjugate pipeline and partnerships with AstraZeneca and Merck add depth. At the same time, earnings recently fell, profit margins eased and the dividend is not well covered by free cash flow, so income investors need to weigh payout comfort against growth ambition. Heavy R&D spend, reliance on a few blockbuster drugs and funding through external borrowing round out the risks that make this dividend stock more growth tilted than defensive.

Daiichi Sankyo Company’s oncology engine is accelerating, yet the real story lies in how its cash flows, partnerships and payout policy fit together in the analysis report for Daiichi Sankyo Company

Japan Tobacco (TSE:2914)

Overview: Japan Tobacco is a global tobacco and food company that sells cigarettes, cigars, heated and infused tobacco products, as well as frozen foods and seasonings under brands such as Winston, Camel, Möbius and LD in Japan and overseas.

Operations: Japan Tobacco generates about ¥3.6t from Tobacco and roughly ¥162b from Processed Food, with only minor contributions from other activities.

Market Cap: ¥12.5t

Income focused investors may find Japan Tobacco interesting because its core combustible and premium tobacco portfolio is generating higher earnings. Management is putting serious money, about ¥650b over three years, into reduced risk products like heated tobacco and e vapor that could reshape future cash flows. Recent revenue and net income figures for 2026, along with a higher interim dividend, point to stronger profit capacity. However, the 3.87% yield is not well covered by free cash flow and reduced risk products are still unprofitable, which keeps payout risk on the table. In addition, reliance on Japan, regulatory and tax pressure and board turnover create a situation where dividend appeal and execution risk sit side by side in what appears to be a high quality earnings story.

Japan Tobacco’s earnings engine and reduced risk push could be masking a far more complex income story. See how cash flows, payout coverage and regulatory pressure intersect in the analysis report for Japan Tobacco

Seeking Alternatives Before The Crowd Moves

Fresh opportunities do not stay under the radar for long. Before the next breakout gains momentum and prices start moving higher, review these curated ideas while it matters.

• Target reliable balance sheets and steady fundamentals by running the curated list of solid balance sheet and fundamentals (40 results) so you are not caught pursuing stretched stories later.
• Explore potential momentum in critical resources by checking the hand picked 8 top copper producer stocks while these producers are still developing rather than appearing in headline prices.
• Review the carefully filtered 36 robotics and automation stocks to evaluate automation leaders before they move out of your preferred valuation range.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com